08048036315
Diabetes RYBELSUS 7mg Tablets trusted to Canada - Toronto | Phoenix Exim | Global Exporter

1. General Information

RYBELSUS 7 mg Tablets contain semaglutide, a prescription medicine belonging to the GLP-1 receptor agonist class. It is used along with diet and exercise to improve blood-glucose control in adults with type 2 diabetes mellitus. The current U.S. prescribing information also includes reduction of major cardiovascular events in certain adults with type 2 diabetes who are at high cardiovascular risk.

Phoenix Exim, based in Nagpur, India, is presented as a pharmaceutical exporter supplying medicines to international markets including the USA, UK, Australia, Singapore, Canada, South Korea, and UAE, subject to applicable import, prescription, and regulatory requirements in the destination country.

2. Product Information

  • Brand: RYBELSUS
  • Active ingredient: Semaglutide
  • Strength: 7 mg
  • Dosage form: Oral tablet
  • Drug class: GLP-1 receptor agonist
  • Route: Oral
  • Typical role: Blood-glucose management in adults with type 2 diabetes
  • Prescription status: Prescription medicine
  • Manufacturer: Novo Nordisk
  • Available RYBELSUS tablet strengths in the U.S. formulation: 3 mg, 7 mg and 14 mg.

Important: RYBELSUS has different formulations with different dosing schemes in the current U.S. labeling, and the formulations are not interchangeable mg-for-mg. Product packaging and approved indications can also vary by country.

3. Uses of RYBELSUS 7 mg

RYBELSUS 7 mg is prescribed primarily for:

  • Improving blood-glucose control in adults with type 2 diabetes mellitus
  • Use alongside an appropriate diet and exercise program
  • Helping reduce the risk of major cardiovascular events in eligible adults with type 2 diabetes and high cardiovascular risk, according to the current U.S. indication.

It is not intended for treatment of type 1 diabetes.

4. Benefits of This Medicine

When prescribed appropriately, RYBELSUS may:

  • Help lower and control blood glucose levels
  • Support improved glycemic control when combined with diet and exercise
  • Reduce appetite in some patients
  • Delay gastric emptying, contributing to its effects on glucose regulation
  • Provide an oral GLP-1 receptor agonist option rather than an injectable GLP-1 medicine
  • In eligible patients, reduce the risk of major cardiovascular events according to the current U.S. prescribing information.

Individual results vary, and the medicine should be used under medical supervision.

5. Side Effects of RYBELSUS 7 mg

RYBELSUS can cause gastrointestinal and other adverse effects. Important potential side effects include:

  • Nausea
  • Abdominal pain
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
  • Pancreatitis
  • Gallbladder problems
  • Hypoglycemia, particularly when used with insulin or insulin secretagogues
  • Diabetic retinopathy complications
  • Serious allergic reactions
  • Severe gastrointestinal reactions.

The prescribing information contains a boxed warning concerning thyroid C-cell tumors observed in rodents. It is not known whether this risk applies to humans. RYBELSUS is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

6. Common Side Effects

The commonly reported adverse reactions occurring in at least 5% of patients include:

  1. Nausea
  2. Abdominal pain
  3. Diarrhea
  4. Decreased appetite
  5. Vomiting
  6. Constipation

If side effects are persistent, severe, or concerning, the patient should contact their healthcare professional.

7. How to Use RYBELSUS 7 mg

Take RYBELSUS exactly as prescribed by the healthcare professional.

For the R1 formulation described in the current U.S. labeling:

  • The usual initial dose is 3 mg once daily for 30 days.
  • It is then increased to 7 mg once daily.
  • If additional glycemic control is required, the healthcare professional may increase the dose after an appropriate period.

For administration:

  • Take it in the morning on an empty stomach.
  • Take it with no more than 4 ounces of plain water.
  • Wait at least 30 minutes before eating, drinking other beverages, or taking other oral medicines.
  • Swallow the tablet whole.
  • Do not split, crush, or chew the tablet.

Do not change the dose or dosing schedule without medical advice.

8. How RYBELSUS Works

Semaglutide is a GLP-1 receptor agonist. It acts similarly to the naturally occurring hormone GLP-1.

Its actions include:

  • Increasing insulin secretion when blood glucose is elevated
  • Reducing glucagon secretion in a glucose-dependent manner
  • Slowing gastric emptying
  • Helping regulate appetite and food intake

Together, these effects can help improve blood-glucose control.

9. Safety Advice

Before using RYBELSUS, patients should tell their healthcare professional about their medical history and all medicines they take.

Important precautions include:

  • Do not use if you or a family member has had medullary thyroid carcinoma (MTC) or if you have MEN 2.
  • Do not use if you have previously experienced a serious allergic reaction to semaglutide or its ingredients.
  • Seek medical attention if symptoms suggesting pancreatitis occur, such as severe or persistent abdominal pain.
  • Patients with diabetic retinopathy should be appropriately monitored.
  • Combining RYBELSUS with insulin or certain diabetes medicines can increase the risk of hypoglycemia.
  • Tell healthcare professionals about RYBELSUS before surgery or procedures involving general anesthesia or deep sedation.
  • Discuss pregnancy and breastfeeding with a healthcare professional before use. The current U.S. labeling recommends discontinuing semaglutide at least 2 months before a planned pregnancy.
  • RYBELSUS can delay gastric emptying and may affect absorption of some oral medicines, particularly medicines with a narrow therapeutic index.

10. Frequently Asked Questions

Q1. What is RYBELSUS 7 mg used for?
RYBELSUS 7 mg is used with diet and exercise to improve blood-glucose control in adults with type 2 diabetes.

Q2. What is the active ingredient in RYBELSUS?
The active ingredient is semaglutide.

Q3. Is RYBELSUS an injection?
No. RYBELSUS is an oral tablet containing semaglutide.

Q4. When should RYBELSUS be taken?
It is generally taken once daily in the morning on an empty stomach with a small amount of plain water, followed by a waiting period of at least 30 minutes before food, beverages, or other oral medicines.

Q5. Can RYBELSUS 7 mg be used for type 1 diabetes?
No. RYBELSUS is not indicated for treatment of type 1 diabetes.

Q6. Can RYBELSUS be used for weight loss?
Semaglutide can affect appetite and body weight, but RYBELSUS should be used according to its approved indication and a healthcare professional's advice. Do not self-medicate for weight management.

Q7. What are the most common side effects?
Nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation are among the most common reported adverse reactions.

Q8. Can I take RYBELSUS with other medicines?
It may be taken with other medicines when prescribed, but RYBELSUS can delay gastric emptying and may affect absorption of some oral medicines. Tell your healthcare professional about all medicines you use.

Q9. Is RYBELSUS 7 mg available in other strengths?
The U.S. R1 formulation is available as 3 mg, 7 mg and 14 mg tablets. Current labeling also describes a separate R2 formulation with different strengths and dosing, which should not be substituted mg-for-mg.

Q10. Can I switch from another semaglutide medicine to RYBELSUS myself?
No. Switching between semaglutide products or formulations should follow the specific prescribing instructions and be supervised by a healthcare professional.

11. Substitute / Alternative Medicines

There is no universally interchangeable substitute for RYBELSUS 7 mg. Possible therapeutic alternatives may include other medicines used for type 2 diabetes, depending on the patient's condition and doctor's assessment, such as:

  • Other GLP-1 receptor agonist medicines
  • Other glucose-lowering medicines such as metformin
  • SGLT2 inhibitors
  • DPP-4 inhibitors
  • Insulin or other injectable therapies when clinically appropriate

Examples of semaglutide-containing alternatives include Ozempic and Wegovy, but they have different formulations, indications, routes of administration, and dosing instructions. They should not be considered automatic substitutes for RYBELSUS 7 mg. A healthcare professional should select the appropriate alternative.

12. SEO Keywords

RYBELSUS 7mg Tablets, Rybelsus 7 mg exporter from India, Rybelsus 7mg tablets supplier India, Rybelsus semaglutide tablets exporter, Rybelsus 7mg pharmaceutical exporter, semaglutide 7mg tablets supplier, Rybelsus 7mg tablets wholesale supplier, Rybelsus 7mg tablets export from India, Rybelsus 7mg medicine exporter Nagpur, Rybelsus 7mg tablets supplier Nagpur India, genuine Rybelsus 7mg tablets supplier, Rybelsus 7mg tablets for international supply, semaglutide tablets pharmaceutical supplier, Rybelsus 7mg tablets USA supply, Rybelsus 7mg tablets UK supply, Rybelsus 7mg tablets Australia supply, Rybelsus 7mg tablets Singapore supply, Rybelsus 7mg tablets Canada supply, Rybelsus 7mg tablets South Korea supply, Rybelsus 7mg tablets UAE supply, type 2 diabetes medicine exporter India, semaglutide medicine exporter India, GLP-1 medicine supplier India, pharmaceutical exporter from Nagpur India, Phoenix Exim Rybelsus supplier.

Aug 21st, 2026 12:59 PM

Keywords